| CAHR Abstracts 2002 |
CLINICAL SCIENCES / SCIENCES CLINIQUES
POSTER PRESENTATIONS/ PRÉSENTATIONS D’AFFICHE
[229P] SAQUINAVIR (SQV)-BASED THERAPY WITHIN A
DIRECTLY OBSERVED THERAPY (MAT/DOT) FOR THE MANAGEMENT OF HIV-INFECTED INTRAVENOUS
DRUG USERS (IDUs) IN A METHADONE (MET) PROGRAM
Jennie Prasad1, Stanley de Vlaming2,3, Michelle
Jones1, Annabel Mead2,3, Nadine Smith3, Brian
Conway1,2,3
1Department of Pharmacology and Therapeutics, University of British
Columbia, Vancouver, British Columbia; 2Pender Community Health Centre,
Vancouver, British Columbia; 3Vancouver Coastal Health Authority,
Vancouver, British Columbia
[230P]
COMPARISON OF CD4 AND CD8 LYMPHOCYTE RECOVERY IN HIV POSITIVE PATIENTS TAKING
PROTEASE INHIBITOR VERSUS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR-BASED
REGIMENS
M Jamil, J Douglas, K Thompson, WF Schlech
Department of Medicine, Dalhousie University, Halifax, Nova Scotia
[231P] ONTARIO PATTERNS OF ANTIRETROVIRAL UTILIZATION:
1997 TO 2000
A Rachlis1, C Jones2, R Remis3,
C Major4
1Sunnybrook and Women’s College Health Sciences Centre, University
of Toronto; 2Ontario HIV Treatment Network; 3University
of Toronto; 4HIV Laboratory, Ontario Ministry of Health and Long-Term
Care
[232P] NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
USE IS NOT ASSOCIATED WITH INCREASED MORTALITY AMONG PERSONs INITIATING ANTIRETROVIRAL
THERAPY IN A POPULATION-BASED SETTING
Robert S Hogg, Katherine Heath, Benita Yip, Julio SG Montaner
[233P] EVALUATION OF PATIENTS RECEIVING LONG-TERM
TWO-DRUG ANTIRETROVIRAL THERAPY (ART)
Kevin Levitt, Sharmistha Das, Brian Conway
Department of Pharmacology & Therapeutics, University of British Columbia, Vancouver,
British Columbia
[234P] POPULATION AND INDIVIDUAL COSTS OF HIV
SERVICE PROVISION: THE IMPACT OF HAART 1996-1999
EJ Beck1,2, S Mandalia2, D Parmar2,
A Miners2, M Youle2, B Gazzard2, M Fisher3,
J Innes3, M Johnson3, G Kinghorn3, A Pozniak3,
A Tang3, I Williams3 for the NPMS-HHC Steering Group
1McGill University; 2NPMS-HHC Coordinating and Analysis Centre,
Chelsea and Westminster Hospital, London, United Kingdom; 3NPMS-HHC
Sites, England
[235P]
COMPARATIVE STUDY OF THE ANTIVIRAL EFFECT OF A STANDARD TRIPLE DRUG REGIMEN
(SDR) AGAINST A ONCE DAILY INVESTIGATIONAL DRUG REGIMEN (IDR): CTN 118
DP Zarowny, L McAfee, J Gill, J Gilmour, M Harris, R Lalonde,
D Rouleau, F Smaill, C Tsoukas, JSG Montaner, Canadian HIV Trials Network
[236P] EFFECTIVENESS OF PATIENT SUPPORT STRATEGIES
FOR IMPROVING HAART ADHERENCE IN HIV-INFECTED INDIVIDUALS: A SYSTEMATIC REVIEW
OF CONTROLLED TRIALS
Laura Park-Wyllie, Tony Antoniou, Ahmed Bayoumi, Richard Glazier
St Michael’s Hospital, Toronto, Ontario
[237P] VIROLOGIC AND IMMUNOLOGIC RESPONSES OF
281 ARV-EXPERIENCED PATIENTS ENROLLED IN THE LOPINAVIR/RITONAVIR (LPV/r) EXPANDED
ACCESS PROGRAM (EAP) IN TORONTO, CANADA
M Loutfy, C Thompson, M Trpeski, C Kovacs, A Rachlis, J Goodhew,
G Rubin, K Gough, S Walmsley
University of Toronto, Toronto, Ontario
[238P] OUTCOMES OF ANTIRETROVIRAL (ARV)-EXPERIENCED
PATIENTS INITIATING A SALVAGE REGIMEN CONTAINING AMPRENAVIR AS THE PROTEASE
INHIBITOR (PI)
M Loutfy, C Thompson, M Trpeski, A Rachlis, S Walmsley
University of Toronto, Toronto, Ontario
[239P] USE OF DELAVIRDINE (DLV) AND LOPINAVIR/r
(LPV) IN HEAVILY PRE-TREATED PATIENTS
Michelle Jones, Salima Jutha, Jennie Prasad, Brian Conway
Department of Pharmacology & Therapeutics, University of British Columbia, Vancouver,
British Columbia
[240P] EFFECT OF NONNUCLEOSIDES (NNRTIs) ON TROUGH
PLASMA LEVELS OF CONCOMITANT SAQUINAVIR-SGC (SQV) AND LOPINAVIR/RITONAVIR (LPV/RTV)
M Harris, C Alexander, L Ting, J Mostyn, S Guillemi, PR Harrigan,
MV O’Shaughnessy, JSG Montaner
BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia
[241P] LACK OF AN ASSOCIATION BETWEEN PROTEASE
INHIBITORS USE AND SEXUAL DYSFUNCTION IN PATIENTS WITH HIV INFECTION
L McGregor1, JB Angel2,3, JJ Clinch3, P
Giguère1
1Department of Pharmacy and 2Department of Medicine, Ottawa
Hospital; 3Ottawa Health Research Institute, Ottawa, Ontario
[242P] LIPID PROFILE CHANGES IN 245 PATIENTS ON
LOPINAVIR/RITONAVIR (LPV/r) AND THE RESPONSE OF 45 OF THOSE PATIENTS TO LIPID-LOWERING
AGENTS (LLAS)
M Loutfy, C Thompson, M Trpeski, C Kovacs, A Rachlis, J Goodhew, G Rubin,
K Gough, S Walmsley
University of Toronto, Toronto, Ontario
[243P] ACUTE PANCREATITIS DUE TO PROTEASE INHIBITOR
CONTAINING REGIMEN TREATED WITH PLASMAPHERESIS
JP Routy1, S Bruce1, MR Boulassel1,
GRH Smith1, DW Blank2, BM Gilfix2
1Immunodeficiency Service; 2Division of Clinical Biochemistry,
McGill University Health Centre, Montreal, Quebec
[244P] POINT PREVALENCE OF HYPERLIPIDEMIA IN HIV
PATIENTS
Tasha Muise1, Nancy Hiltz1, Kathryn Slayter1,2,
David Haase1,2
1Dalhousie University; 2QEII Health Sciences Centre, Halifax,
Nova Scotia
[245P] DYSLIPIDEMIA AND BODY COMPOSITION EFFECTS
OF TESTOSTERONE CYPIONATE (TC) IN A GROUP OF PEOPLE LIVING WITH HIV/AIDS (PHAs)
IN ONTARIO, CANADA
S Tenzif1, P Ford2, W Wobeser2, B Ross2,
D Jenkins3, D Martin2
1The Riverdale Hospital, Toronto, Ontario; 2Queen’s University,
Kingston, Ontario; 3University of Toronto, Toronto, Ontario
[246P] VISCERAL ADIPOSITY IN A
GROUP OF MEN ON ANTIRETROVIRAL THERAPY IS ASSOCIATED WITH LOW SERUM TESTOSTERONE
W Wobeser1, P Ford 1, S Tenzif2,
R Ross1
1Queen’s University, Kingston, Ontario; 1Riverdale Hospital,
Toronto, Ontario
[247P] USE OF LIPID-LOWERING DRUGS BY PATIENTS
RECEIVING HIGHLY ACTIVE ANTIRETROVIRAL THERAPY
Elizabeth Phillips1,2, Ahmed M Bayoumi1,2,
Janet M Raboud3,4, Peggy Millson3, Gregory Robinson, Anita
Rachlis1,3
1Sunnybrook and Womens’ College Health Sciences Centre; 2Ontario
HIV Treatment Network; 3University of Toronto; 4Mount
Sinai Hospital
[248P] INCREASING RATE OF CARDIAC
PROCEDURES AMONG HIV-POSITIVE INDIVIDUALS ON ANTIRETROVIRAL THERAPY FROM 1993-2001
P Braitstein1,2, B Yip1, J Montaner1,3,
A Levy1,2, J Joseph2, M Kiely4, MV O’Shaughnessy1,5,
RS Hogg1,2
1British Columbia Centre for Excellence in HIV/AIDS; 2Department
of Health Care and Epidemiology, University of British Columbia; 3Department
of Medicine, University of British Columbia; 4British Columbia Cardiac
Registry; 5Department of Pathology, University of British Columbia,
Vancouver, British Columbia
[249P] PREDICTORS OF CLINICALLY RELEVANT HEPATOTOXICITY
(HT) IN HIV-HCV CO-INFECTED INDIVIDUALS
CL Cooper, MA Parbhakar, JB Angel
Division of Infectious Diseases, Ottawa Hospital, University of Ottawa, Ottawa,
Ontario
[250P] SCREENING FOR HEPATITIS C VIRUS (HCV) INFECTION
AMONG PREGNANT WOMEN IN A LARGE CITY HOSPITAL: AN EVALUATION OF PERFORMANCE
M Boucher, N Lapointe, J Samson
Ste-Justine Hospital, Centre Maternel et Infantile sur le SIDA, University of
Montreal, Montreal, Quebec
[251P] THE SAFETY AND EFFICACY OF PROTEASE INHIBITORS
(PIs) IN HEPATITIS C (HCV) CO-INFECTED PATIENTS
D Dieterich1, M Fischl2, D Rimland3,
G Sepulveda4
1Liberty Medical, LLP, New York, New York; 2University
of Miami, Miami, Florida; 3Atlanta VA Medical Center, Atlanta, Georgia;
4Programa SIDA, Ponce, Puerta Rico
[252P] FACING A NEW EPIDEMIC (?) MOLECULAR EPIDEMIOLOGY
OF HIV AMONG MOTHER AND CHILD COHORT IN MONTREAL
N Lapointe, J Samson, M Boucher
Ste-Justine Hospital, Centre Maternel et Infantile sur le SIDA, University of
Montreal, Montreal, Quebec
[253P] FAILURE OF EARLY DETECTION
OF PERINATAL TRANSMISSION OF A NON-B CLADE HIV-1 STRAIN WITH THE ROCHE (VERSION
1.5) DNA-BASED POLYMERASE CHAIN REACTION (PCR)
A Bitnun1, S King1, C Major2, S Li1,
S Read1
1Division of Infectious Diseases, The Hospital for Sick Children, University
of Toronto, Toronto, Ontario; 2Laboratories Branch, Ministry of Health
and Long Term Care, Toronto, Ontario
[254P] MOLECULAR VARIANT ANALYSIS OF PERSISTENT
HPV-52 INFECTION IN HIV-INFECTED WOMEN
J Aho, C Hankins, F Lang, The Canadian Women’s HIV Study Group, F Coutlée
Centre Hospitalier de l’Université de Montréal, Montreal University, and Department
of Epidemiology and Biostatistics, McGill University, Montreal, Quebec
[255P] COMPARISON OF SELF-OBTAINED
AND PHYSICIAN-OBTAINED CERVICAL SWAB SAMPLES FOR DETECTION OF HUMAN PAPILLOMAVIRUS
(HPV) DNA IN WOMEN INFECTED WITH HIV
F Coutlée, C Hankins, S Walmsley, D Money, K Pourreaux,
P Forest, J-O Shu, Canadian Women’s HIV Study Group
Centre Hospitalier de l’Université de Montréal; Direction de la santé publique
de Montréal; Department of Epidemiology and Biostatistics, McGill University;
Toronto General Hospital, Toronto; Oak Tree Clinic, Vancouver
[256P] TREATMENT INTERRUPTION
IN HIV INFECTED CHILDREN: A DESCRIPTIVE STUDY
Ariane Alimenti, Dominique Khoo, David Burdge, Jack Forbes
Oak Tree Clinic; Children’s and Women’s Health Centre of British Columbia; University
of British Columbia, Vancouver, British Columbia
[257P] RCT TO ASSESS THE EFFECT OF WITHDRAWAL
OF INTRAVENOUS IMMUNE GLOBULIN (IVIG) THERAPY FOR SELECTED CHILDREN WITH HIV
INFECTION
G Grisaru-Soen, W Lau, C Arneson, D Louch, SE Read, A Bitnun, D Stephens,
SM King
The Hospital for Sick Children and University of Toronto, Toronto, Ontario
[258P] GENOTYPIC HIV-1 DRUG RESISTANCE AMONG RECENT
SEROCONVERTERS: RESULTS FROM THE POLARIS HIV SEROCONVERSION STUDY
R Pilon1, P Sandstrom1, A Burchell2,
L Calzavara2, C Major3, S Read4, K Logue5,
M Ostrowski5, K Gough5, A Rachlis6, Polaris
HIV Study Team
1Centre for Infectious Disease Prevention and Control, Health Canada;
2HIV Studies Unit, University of Toronto; 3Ontario Ministry
of Health, Toronto; 4Hospital for Sick Children, Toronto; 5Faculty
of Medicine, University of Toronto; 6Sunnybrook and Women’s College
Health Sciences Centre, University of Toronto, Ontario
[259P] PATTERNS OF GENOTYPIC HIV DRUG RESISTANCE
IN ONTARIO
C Swantee1, C Major1, R Remis2, M Fearon1,
K Wu1, A Bayoumi2, A Rachlis2, R Kort1,
F McGee1, R Galli3, PR Harrigan3, S Read2,
Ontario HIV Genotyping Working Group
1Ontario Ministry of Health and Long-Term Care, 2University
of Toronto, Toronto, Ontario 3BC Centre for Excellence in HIV/AIDS,
Vancouver, British Columbia
[260P] ACCESS TO GENOTYPIC RESISTANCE TESTING
IN ONTARIO
JM Raboud1,2, R Saskin3, C Major4, A Rachlis5,6,
P Millson2, G Robinson7, RS Remis2,4, AM Bayoumi6,7
1Division of Infectious Diseases, University Health Network, University
of Toronto; Department of Public Health Sciences, University of Toronto; 3Department
of Microbiology, Mount Sinai Hospital; 4Ontario Ministry of Health;
5Sunnybrook Health Sciences Centre; 6Faculty of Medicine,
University of Toronto; 7Ontario HIV Treatment Network
[261P] ANTIRETROVIRAL PRESCRIBING PATTERNS AFTER
GENOTYPIC RESISTANCE TESTING IN THE HIV ONTARIO OBSERVATIONAL DATABASE
Ahmed M Bayoumi1,2, Carol Major3, Tonia Forte1,2,
Peggy Millson1,2, Gregory Robinson, Robert S Remis2, Anita
Rachlis2,4
1Ontario HIV Treatment Network; 2University of Toronto;
3Ontario Public Health Laboratory; 4Sunnybrook and Women’s
College Health Sciences Centre
[262P] PROCEDURE FOR SUSTAINING RULES BASED DRUG
RESISTANCE INTERPRETATION ALGORITHMS
CL Reid1, DL Winslow1, K Smith1, JD
Baxter2, F Brun-Vézinet3, B Clotet4, RM Grant5,
C Loveday6, TC Merigan7, W O’Brien8, MA Wainberg9,
JM Schapiro7
1Visible Genetics, Toronto, Ontario; 2Cooper Hospital/RWJ Medical
School, Camden, New Jersey; 3Hôpital Bichat-Caude Bernard, Paris,
France; 4Hosp. Universitari Germans Trias i Pujol, Barcelona,
Spain; 5Gladstone/UCSF, San Francisco, California; 6Royal
Free/University College Medical School, London, United Kingdom; 7Stanford
University, Palo Alto, California; 8University of Texas Medical Branch,
Galveston, Texas; 9McGill University AIDS Center/Jewish General Hospital,
Montreal, Quebec
[263P] COST ANALYSIS OF TESTING ALGORITHMS FOR
ROCHE AMPLICOR HIV-1 MONITOR STANDARD AND ULTRASENSITIVE: ACHIEVING ACCURACY
AT LOWEST COST
CH Sherlock1,3, D Guh2, JSG Montaner2,3,
MV O’Shaughnessy1,2,3, AH Anis2,3
Department of Laboratory Medicine, Canadian HIV Trials Network and BC Centre
for Excellence in HIV/AIDS, Providence Health Care, Vancouver, British Columbia
[264P] A MULTICENTER HIV DRUG RESISTANCE TESTING
PROGRAM IN QUÉBEC
H Charest1, P Gonin1, D Murphy1, B Brenner2,
C Matte3, M Wainberg2, M Roger3, M Fauvel1
1Laboratoire de santé publique du Québec, Ste-Anne-de-Bellevue, Québec;
2Jewish General Hospital, Montréal, Québec; 3CHUM-Hôpital
Notre-Dame, Montréal, Québec
[265P] NATIONAL HIV IMMUNOLOGY
LABORATORY IN BUSINESS TO ASSESS IMMUNOPHENOTYPING LABORATORY PERFORMANCE FOR
OVER A DECADE
F Mandy, M Bergeron, C Houle, S Faucher, Z Solajic, S Phaneuf, A Sherring,
N Soucy, T Ding, D Bogdanovic, C Chabot
National HIV Immunology Laboratory, Health Canada, Ottawa, Ontario